Gajek G, Marciniak B, Lewkowski J, Kontek R. Antagonistic Effects of CAPE (a Component of Propolis) on the Cytotoxicity and Genotoxicity of Irinotecan and SN38 in Human Gastrointestinal Cancer Cells In Vitro. Molecules. 2020;25: pubmed publisher

Guadagni S, Fiorentini G, De Simone M, Masedu F, Zoras O, Mackay A, et al. Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study. J Cancer Res Clin Oncol. 2020;146:205-219 pubmed publisher

Bojko A, Czarnecka Herok J, Charzynska A, Dabrowski M, Sikora E. Diversity of the Senescence Phenotype of Cancer Cells Treated with Chemotherapeutic Agents. Cells. 2019;8: pubmed publisher

Ghosh A, Bhattacharjee S, Chowdhuri S, Mallick A, Rehman I, Basu S, et al. SCAN1-TDP1 trapping on mitochondrial DNA promotes mitochondrial dysfunction and mitophagy. Sci Adv. 2019;5:eaax9778 pubmed publisher

Feng D, Qin B, Pal K, Sun L, Dutta S, Dong H, et al. BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. Oncogene. 2019;38:6752-6766 pubmed publisher

Guillaume L, Rigal L, Fehrenbach J, Séverac C, Ducommun B, Lobjois V. Characterization of the physical properties of tumor-derived spheroids reveals critical insights for pre-clinical studies. Sci Rep. 2019;9:6597 pubmed publisher

Forsythe S, Mehta N, Devarasetty M, Sivakumar H, GMEINER W, Soker S, et al. Development of a Colorectal Cancer 3D Micro-tumor Construct Platform From Cell Lines and Patient Tumor Biospecimens for Standard-of-Care and Experimental Drug Screening. Ann Biomed Eng. 2019;: pubmed publisher

Kari V, Raul S, Henck J, Kitz J, Kramer F, Kosinsky R, et al. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness. Clin Epigenetics. 2019;11:4 pubmed publisher

Votanopoulos K, Mazzocchi A, Sivakumar H, Forsythe S, Aleman J, Levine E, et al. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study. Ann Surg Oncol. 2019;26:139-147 pubmed publisher

Nilsson K, Wu C, Kajitani N, Yu H, Tsimtsirakis E, Gong L, et al. The DNA damage response activates HPV16 late gene expression at the level of RNA processing. Nucleic Acids Res. 2018;46:5029-5049 pubmed publisher

Silva J, Aivio S, Knobel P, Bailey L, Casali A, Vinaixa M, et al. EXD2 governs germ stem cell homeostasis and lifespan by promoting mitoribosome integrity and translation. Nat Cell Biol. 2018;20:162-174 pubmed publisher

Ozden O, Bishehsari F, Bauer J, Park S, Jana A, Baik S, et al. Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer. Sci Rep. 2016;6:26273 pubmed publisher

Wang J, Hu K, Guo J, Cheng F, Lv J, Jiang W, et al. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK. Nat Commun. 2016;7:11363 pubmed publisher

Sabir S, Sahota N, Jones G, Fry A. Loss of Nek11 Prevents G2/M Arrest and Promotes Cell Death in HCT116 Colorectal Cancer Cells Exposed to Therapeutic DNA Damaging Agents. PLoS ONE. 2015;10:e0140975 pubmed publisher

Ye X, Fan L, Van Horn R, Nakai R, Ohta Y, Akinaga S, et al. A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models. Mol Cancer Ther. 2015;14:2463-72 pubmed publisher

Fukami T, Kariya M, Kurokawa T, Iida A, Nakajima M. Comparison of substrate specificity among human arylacetamide deacetylase and carboxylesterases. Eur J Pharm Sci. 2015;78:47-53 pubmed publisher

Itoh N, Santa T, Kato M. Rapid evaluation of the quantity of drugs encapsulated within nanoparticles by high-performance liquid chromatography in a monolithic silica column. Anal Bioanal Chem. 2015;407:6429-34 pubmed publisher

Choi S, Lee Y, Kwak P, Lee J, Kim S, Lee S, et al. Clinically applicable human adipose tissue-derived mesenchymal stem cells delivering therapeutic genes to brainstem gliomas. Cancer Gene Ther. 2015;22:302-11 pubmed publisher

Yang M, Xu Z, Wang Q, Zhang A, Min J. A hyposensitive anticancer drug induces higher surface expression and release of heat shock proteins in a human hepatocellular carcinoma cell line. Mol Med Rep. 2015;12:2879-85 pubmed publisher

Hu T, Weng S, Tang W, Xue R, Chen S, Cai G, et al. Overexpression of BIRC6 Is a Predictor of Prognosis for Colorectal Cancer. PLoS ONE. 2015;10:e0125281 pubmed publisher

Yagishita S, Fujita Y, Kitazono S, Ko R, Nakadate Y, Sawada T, et al. Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer. Mol Cancer Ther. 2015;14:1414-23 pubmed publisher

Tanaka S, Hosokawa M, Yonezawa T, Hayashi W, Ueda K, Iwakawa S. Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells. Biol Pharm Bull. 2015;38:435-40 pubmed publisher

Wang W, Sivakumar W, Torres S, Jhaveri N, Vaikari V, Gong A, et al. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals. Neurosurg Focus. 2015;38:E8 pubmed publisher

Teft W, Welch S, Lenehan J, Parfitt J, Choi Y, Winquist E, et al. OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. Br J Cancer. 2015;112:857-65 pubmed publisher

Liu X, Hummon A. Quantitative determination of irinotecan and the metabolite SN-38 by nanoflow liquid chromatography-tandem mass spectrometry in different regions of multicellular tumor spheroids. J Am Soc Mass Spectrom. 2015;26:577-86 pubmed publisher

Chang T, Shiah H, Yang C, Yeh K, Cheng A, Shen B, et al. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother Pharmacol. 2015;75:579-86 pubmed publisher

Zhang C, Xu Y, Gao P, Lü J, Li X, Liu D. Down-regulation of carboxylesterases 1 and 2 plays an important role in prodrug metabolism in immunological liver injury rats. Int Immunopharmacol. 2015;24:153-158 pubmed publisher

Payen L, Honorat M, Guitton J, Gauthier C, Bouard C, Lecerf Schmidt F, et al. MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts. Oncotarget. 2014;5:11957-70 pubmed

Cosco D, Paolino D, De Angelis F, Cilurzo F, Celia C, Di Marzio L, et al. Aqueous-core PEG-coated PLA nanocapsules for an efficient entrapment of water soluble anticancer drugs and a smart therapeutic response. Eur J Pharm Biopharm. 2015;89:30-9 pubmed publisher

Trouilloud I, Dupont Gossard A, Malka D, Artru P, Gauthier M, Lecomte T, et al. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM). Eur J Cancer. 2014;50:3116-24 pubmed publisher

Ng K, Meyerhardt J, Chan A, Sato K, Chan J, Niedzwiecki D, et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst. 2015;107:345 pubmed publisher

Croucher J, Iyer R, Li N, Molteni V, Loren J, Gordon W, et al. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts. Cancer Chemother Pharmacol. 2015;75:131-41 pubmed publisher

Kimura H, Ikeda T, Nakayama H, Sakai Y, Fujii T. An on-chip small intestine-liver model for pharmacokinetic studies. J Lab Autom. 2015;20:265-73 pubmed publisher

Eba J, Shimokawa T, Nakamura K, Shibata T, Misumi Y, Okamoto H, et al. A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201). Jpn J Clin Oncol. 2015;45:115-8 pubmed publisher

Hochster H, Uboha N, Messersmith W, Gold P, ONeil B, Cohen D, et al. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015;75:17-23 pubmed publisher

Buck A, Halbritter S, Späth C, Feuchtinger A, Aichler M, Zitzelsberger H, et al. Distribution and quantification of irinotecan and its active metabolite SN-38 in colon cancer murine model systems using MALDI MSI. Anal Bioanal Chem. 2015;407:2107-16 pubmed publisher

Horiguchi H, Endo M, Miyamoto Y, Sakamoto Y, Odagiri H, Masuda T, et al. Angiopoietin-like protein 2 renders colorectal cancer cells resistant to chemotherapy by activating spleen tyrosine kinase-phosphoinositide 3-kinase-dependent anti-apoptotic signaling. Cancer Sci. 2014;105:1550-9 pubmed publisher

Kalra A, Kim J, Klinz S, Paz N, Cain J, Drummond D, et al. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Cancer Res. 2014;74:7003-13 pubmed publisher

Jossé R, Martin S, Guha R, Ormanoglu P, Pfister T, Reaper P, et al. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014;74:6968-79 pubmed publisher

Hashimoto N, Tsunedomi R, Yoshimura K, Watanabe Y, Hazama S, Oka M. Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs. BMC Cancer. 2014;14:722 pubmed publisher

Brennan R, Furman W, Mao S, Wu J, Turner D, Stewart C, et al. Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol. 2014;74:1191-8 pubmed publisher

Hoch U, Staschen C, Johnson R, Eldon M. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol. 2014;74:1125-37 pubmed publisher

Yoneyama H, Takizawa Hashimoto A, Takeuchi O, Watanabe Y, Atsuda K, Asanuma F, et al. Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones. Anticancer Drugs. 2015;26:90-100 pubmed publisher

Kyle A, Baker J, Gandolfo M, Reinsberg S, Minchinton A. Tissue penetration and activity of camptothecins in solid tumor xenografts. Mol Cancer Ther. 2014;13:2727-37 pubmed publisher

Ikeya T, Shibutani M, Maeda K, Sugano K, Nagahara H, Ohtani H, et al. Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer. J Cancer Res Clin Oncol. 2015;141:307-13 pubmed publisher

Nonnenmacher L, Westhoff M, Fulda S, Karpel Massler G, Halatsch M, Engelke J, et al. RIST: a potent new combination therapy for glioblastoma. Int J Cancer. 2015;136:E173-87 pubmed publisher

Yasui H, Muro K, Shimada Y, Tsuji A, Sameshima S, Baba H, et al. A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. J Cancer Res Clin Oncol. 2015;141:153-60 pubmed publisher

Casadó A, Sagristá M, Mora M. Formulation and in vitro characterization of thermosensitive liposomes for the delivery of irinotecan. J Pharm Sci. 2014;103:3127-38 pubmed publisher

Yamasaki S, Tanimoto K, Kohno K, Kadowaki M, Takase K, Kondo S, et al. UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan. Ann Hematol. 2015;94:65-9 pubmed publisher

Chaix M, Vincent J, Lorgis V, Ghiringhelli F. FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer. Oncology. 2014;87:148-58 pubmed publisher

Tomita R, Todoroki K, Machida K, Nishida S, Maruoka H, Yoshida H, et al. Assessment of the efficacy of anticancer drugs by amino acid metabolomics using fluorescence derivatization-HPLC. Anal Sci. 2014;30:751-8 pubmed

Ihn M, Kang S, Kim D, Oh H, Lee S, Hong S. Risk factors for bowel dysfunction after sphincter-preserving rectal cancer surgery: a prospective study using the Memorial Sloan Kettering Cancer Center bowel function instrument. Dis Colon Rectum. 2014;57:958-66 pubmed publisher

Choi E, Park J, Yoon K, Bae S. Evaluation of the in vitro/in vivo potential of five berries (bilberry, blueberry, cranberry, elderberry, and raspberry ketones) commonly used as herbal supplements to inhibit uridine diphospho-glucuronosyltransferase. Food Chem Toxicol. 2014;72:13-9 pubmed publisher

Nittayacharn P, Manaspon C, Hongeng S, Nasongkla N. HPLC analysis and extraction method of SN-38 in brain tumor model after injected by polymeric drug delivery system. Exp Biol Med (Maywood). 2014;239:1619-29 pubmed publisher

Wei W, Liu Z, Chen X, Bi F. Chemosensitivity of resistant colon cancer cell lines to lobaplatin, heptaplatin, and dicycloplatin. Int J Clin Pharmacol Ther. 2014;52:702-7 pubmed publisher

Yamamura Y, Tsuchikawa T, Miyauchi K, Takeuchi S, Wada M, Kuwatani T, et al. The key role of calreticulin in immunomodulation induced by chemotherapeutic agents. Int J Clin Oncol. 2015;20:386-94 pubmed publisher

Nakamura T, Yamashita K, Sato T, Ema A, Naito M, Watanabe M. Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors. Int J Radiat Oncol Biol Phys. 2014;89:547-55 pubmed publisher

Park D, Won J, Cho A, Yun H, Heo J, Hwhang T, et al. Determination of irinotecan and its metabolite SN-38 in rabbit plasma and tumors using a validated method of tandem mass spectrometry coupled with liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;962:147-152 pubmed publisher

Takahashi T, Namiki K, Matsumoto H, Konno F, Mitsui K, Yoshida R. [A case of advanced rectal cancer that showed complete response to the addition of XELOX+bevacizumab therapy to preoperative chemoradiotherapy with S-1/CPT-11]. Gan To Kagaku Ryoho. 2014;41:653-5 pubmed

Goldwirt L, Beccaria K, Carpentier A, Farinotti R, Fernandez C. Irinotecan and temozolomide brain distribution: a focus on ABCB1. Cancer Chemother Pharmacol. 2014;74:185-93 pubmed publisher

Kosakowska Cholody T, Lin J, Srideshikan S, Scheffer L, Tarasova N, Acharya J. HKH40A downregulates GRP78/BiP expression in cancer cells. Cell Death Dis. 2014;5:e1240 pubmed publisher

Yu J, Han J, Gao Y. Biotransformation of glucoaurantio-obtusin towards aurantio-obtusin increases the toxicity of irinotecan through increased inhibition towards SN-38 glucuronidation. Phytother Res. 2014;28:1577-80 pubmed publisher

Takahashi N, Yamada Y, Taniguchi H, Honma Y, Iwasa S, Kato K, et al. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal ca. Arch Med Res. 2014;45:366-74 pubmed publisher

Miyamoto M, Misawa S. [Case report of chemotherapeutic control of a gastric cancer producing granulocyte-colony stimulating factor]. Nihon Shokakibyo Gakkai Zasshi. 2014;111:748-55 pubmed

Barbazan J, Muinelo Romay L, Vieito M, Candamio S, Díaz López A, Cano A, et al. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer. Int J Cancer. 2014;135:2633-43 pubmed publisher

Shimizu M, Fukami T, Nakajima M, Yokoi T. Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase. Drug Metab Dispos. 2014;42:1103-9 pubmed publisher

Nielsen D, Palshof J, Larsen F, Jensen B, Pfeiffer P. A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. Cancer Treat Rev. 2014;40:701-15 pubmed publisher

Frese Schaper M, Keil A, Steiner S, Gugger M, Korner M, Kocher G, et al. Low-dose irinotecan improves advanced lupus nephritis in mice potentially by changing DNA relaxation and anti-double-stranded DNA binding. Arthritis Rheumatol. 2014;66:2259-69 pubmed publisher

Chen M, Lee N, Ho T, Hsu H, Kuo C, Kuo W, et al. Resistance to irinotecan (CPT-11) activates epidermal growth factor receptor/nuclear factor kappa B and increases cellular metastasis and autophagy in LoVo colon cancer cells. Cancer Lett. 2014;349:51-60 pubmed publisher

Primrose J, Falk S, Finch Jones M, Valle J, O Reilly D, Siriwardena A, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol. 2014;15:601-11 pubmed publisher

Bruera G, Cannita K, Giordano A, Vicentini R, Ficorella C, Ricevuto E. Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen. Int J Oncol. 2014;44:1820-30 pubmed publisher

Sasaki Y, Hamaguchi T, Arai T, Goto A, Ura T, Muro K, et al. Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients. Anticancer Res. 2014;34:2029-34 pubmed

Iwamoto S, Hazama S, Kato T, Miyake Y, Fukunaga M, Matsuda C, et al. Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. Anticancer Res. 2014;34:1967-73 pubmed

Tang Y, Chen R, Huang Y, Li G, Huang Y, Chen J, et al. Natural compound Alternol induces oxidative stress-dependent apoptotic cell death preferentially in prostate cancer cells. Mol Cancer Ther. 2014;13:1526-36 pubmed publisher

Dʼangelica M, Correa Gallego C, Paty P, Cercek A, Gewirtz A, Chou J, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg. 2015;261:353-60 pubmed publisher

Wu M, Wang X, McGregor N, Pienta K, Zhang J. Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia. Mol Pharmacol. 2014;85:866-76 pubmed publisher

Cao S, Durrani F, Toth K, Rustum Y. Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models. Br J Cancer. 2014;110:1733-43 pubmed publisher

Higuchi K, Tanabe S, Shimada K, Hosaka H, Sasaki E, Nakayama N, et al. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial). Eur J Cancer. 2014;50:1437-45 pubmed publisher

Hoff P, Saragiotto D, Barrios C, del Giglio A, Coutinho A, Andrade A, et al. Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial. J Clin Oncol. 2014;32:1006-11 pubmed publisher

Van Loon K, Venook A. Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities. J Clin Oncol. 2014;32:991-6 pubmed publisher

Ortiz Tudela E, Iurisci I, Beau J, Karaboué A, Moreau T, Rol M, et al. The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy. Int J Cancer. 2014;134:2717-25 pubmed publisher

Jehn C, Böning L, Kröning H, Pezzutto A, Lüftner D. Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer. Eur J Cancer. 2014;50:1269-75 pubmed publisher

Eba J, Kenmotsu H, Tsuboi M, Niho S, Katayama H, Shibata T, et al. A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206). Jpn J Clin Oncol. 2014;44:379-82 pubmed publisher

Chen Y, Chueh F, Yang J, Hsueh S, Lu C, Chiang J, et al. Antitumor effects with apoptotic death in human promyelocytic leukemia HL-60 cells and suppression of leukemia xenograft tumor growth by irinotecan HCl. Environ Toxicol. 2015;30:803-15 pubmed publisher

Lu C, Huang C, Hu H, Tsai H, Huang C, Yu F, et al. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with ir. Transl Res. 2014;164:169-76 pubmed publisher

Ahn G, Park D, Park J, Kim H, Cho J, Rhee S, et al. A rapid, simple and reliable HPLC-triple quadrupole tandem mass spectrometer method for a simultaneous quantification of irinotecan and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN38) in mouse plasma. Biomed Chromatogr. 2014;28:919-22 pubmed publisher

Erbaykent Tepedelen B, Karamil S, Gonen Korkmaz C, Korkmaz K. DNA damage response (DDR) via NKX3.1 expression in prostate cells. J Steroid Biochem Mol Biol. 2014;141:26-36 pubmed publisher

Michel P, Breysacher G, Mornex F, Seitz J, Péré Vergé D, Martel Lafay I, et al. Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. Fédération Francophone de Cancérologie Digestive 0308. Eur J Cancer. 2014;50:1076-83 pubmed publisher

Guabiraba R, Besnard A, Menezes G, Secher T, Jabir M, Amaral S, et al. IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice. Mucosal Immunol. 2014;7:1079-93 pubmed publisher

Bautista F, Paci A, Minard Colin V, Dufour C, Grill J, Lacroix L, et al. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer. 2014;61:1101-3 pubmed publisher

Passot G, Bakrin N, Roux A, Vaudoyer D, Gilly F, Glehen O, et al. Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients. Eur J Surg Oncol. 2014;40:529-535 pubmed publisher

Schmieder R, Hoffmann J, Becker M, Bhargava A, Müller T, Kahmann N, et al. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int J Cancer. 2014;135:1487-96 pubmed publisher

Armstrong A, Dargart J, Reichek J, Walterhouse D, Matossian D, Cohn R, et al. Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis. Pediatr Blood Cancer. 2014;61:949-50 pubmed publisher

Bagatell R, Norris R, Ingle A, Ahern C, Voss S, Fox E, et al. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study. Pediatr Blood Cancer. 2014;61:833-9 pubmed publisher

Venkatramani R, Malogolowkin M, Mascarenhas L. Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab. Pediatr Blood Cancer. 2014;61:756-9 pubmed publisher

Yoshimoto K, Saito H, Munemoto M, Kadoya N, Murata S. [A case of recurrence after resection of gastric cancer successfully treated by combination chemotherapy with CPT-11 and CDDP]. Gan To Kagaku Ryoho. 2013;40:929-32 pubmed

Nishizawa T, Kinoshita S, Sakuno T, Fujiyama Y, Kikuchi M, Kaneko H, et al. [A case of metastatic colon cancer effectively treated by XELOX and IRIS]. Gan To Kagaku Ryoho. 2013;40:807-9 pubmed

Takeda M, Ori T, Ohishi K, Sunayama K. [A case of synchronous liver metastasis originating from advanced gastric cancer treated with combination chemotherapy involving S-1 and surgical intervention]. Gan To Kagaku Ryoho. 2013;40:667-70 pubmed

Katayama K, Nishino T, Takahashi Y, Tanaka T, Okitsu H, Okitsu N. [Approximately four years of survival benefits for a case of gastric cancer postoperative carcinomatous peritonitis by combined modality therapy]. Gan To Kagaku Ryoho. 2013;40:655-8 pubmed

Soda H, Nemoto H, Akatsuka S, Arioka H, Shimada K, Ito T, et al. [Efficacy and safety of cetuximab+irinotecan for unresectable advanced or recurrent colorectal cancer]. Gan To Kagaku Ryoho. 2013;40:605-8 pubmed

Takano M, Goto T, Hirata J, Furuya K, Horie K, Takahashi M, et al. UGT1A1 genotype-specific phase I and pharmacokinetic study for combination chemotherapy with irinotecan and cisplatin: a Saitama Tumor Board study. Eur J Gynaecol Oncol. 2013;34:120-3 pubmed

Saito M, Yano K, Kamigaki T, Goto S. A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA). Anticancer Res. 2013;33:2957-63 pubmed

Sasaki T, Isayama H, Nakai Y, Takahara N, Satoh Y, Takai D, et al. A pilot study of salvage irinotecan monotherapy for advanced biliary tract cancer. Anticancer Res. 2013;33:2619-22 pubmed

Vangara K, Liu J, PALAKURTHI S. Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancer. Anticancer Res. 2013;33:2425-34 pubmed

Eng C. Will PICCOLO affect metastatic colorectal cancer therapy?. Lancet Oncol. 2013;14:679-80 pubmed publisher

Seymour M, Brown S, Middleton G, Maughan T, Richman S, Gwyther S, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 2013;14:749-59 pubmed publisher

Jett J, Schild S, Kesler K, Kalemkerian G. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e400S-e419S pubmed publisher

Akiyoshi K, Yamada Y, Honma Y, Iwasa S, Kato K, Hamaguchi T, et al. KRAS mutations in patients with colorectal cancer as detected by high-resolution melting analysis and direct sequencing. Anticancer Res. 2013;33:2129-34 pubmed

Narayanan G, Barbery K, Suthar R, Guerrero G, Arora G. Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer. Anticancer Res. 2013;33:2077-83 pubmed

Hu J, Kinn J, Zirakzadeh A, Sherif A, Norstedt G, Wikstrom A, et al. The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation. Clin Exp Immunol. 2013;172:490-9 pubmed publisher

Kim K, Kim H, Sym S, Bae K, Hong Y, Chang H, et al. A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2013;71:1609-17 pubmed publisher

Tahara M, Inoue T, Miyakura Y, Horie H, Yasuda Y, Fujii H, et al. Cell diameter measurements obtained with a handheld cell counter could be used as a surrogate marker of G2/M arrest and apoptosis in colon cancer cell lines exposed to SN-38. Biochem Biophys Res Commun. 2013;434:753-9 pubmed publisher

Kim H, Kim J, Kim B, Choi H, Kwon J, Choi D. Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2013;71:1591-7 pubmed publisher

Moreau L, Rajan R, Thirlwell M, Alcindor T. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting. Anticancer Res. 2013;33:1765-8 pubmed

Shishido Y, Ueno S, Yamazaki R, Nagaoka M, Matsuzaki T. ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan. Anticancer Res. 2013;33:1379-86 pubmed

Mohiuddin M, Paulus R, Mitchell E, Hanna N, Yuen A, Nichols R, et al. Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer. Int J Radiat Oncol Biol Phys. 2013;86:523-8 pubmed publisher

Cortejoso L, Garcia M, García Alfonso P, Gonzalez Haba E, Escolar F, Sanjurjo M, et al. Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemother Pharmacol. 2013;71:1463-72 pubmed publisher

Hata T, Fukunaga M, Murata K, Uemura Y, Fukuzaki T, Ota H, et al. A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer. Cancer Chemother Pharmacol. 2013;71:1657-63 pubmed publisher

Patnaik A, Papadopoulos K, Tolcher A, Beeram M, Urien S, Schaaf L, et al. Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. Cancer Chemother Pharmacol. 2013;71:1499-506 pubmed publisher

Shelton J, Waxweiler T, Landry J, Gao H, Xu Y, Wang L, et al. In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells. Int J Radiat Oncol Biol Phys. 2013;86:469-76 pubmed publisher

Wakuda K, Kenmotsu H, Naito T, Akamatsu H, Ono A, Shukuya T, et al. Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer. Am J Clin Oncol. 2015;38:28-32 pubmed publisher

Bandyopadhyay K, Gjerset R. Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines. Biochemistry. 2011;50:704-14 pubmed publisher

Illum H. Irinotecan and radiosensitization in rectal cancer. Anticancer Drugs. 2011;22:324-9 pubmed publisher

Barth S, Briviba K, Watzl B, Jäger N, Marko D, Esselen M. In vivo bioassay to detect irinotecan-stabilized DNA/topoisomerase I complexes in rats. Biotechnol J. 2010;5:321-7 pubmed publisher

Lin C, Ban Y, Lyu Y, Liu L. Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks. J Biol Chem. 2009;284:28084-92 pubmed publisher

Crea F, Giovannetti E, Cortesi F, Mey V, Nannizzi S, Gallegos Ruiz M, et al. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. Mol Cancer Ther. 2009;8:1964-73 pubmed publisher

Goto A. [The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule]. Gan To Kagaku Ryoho. 2006;33 Suppl 1:125-30 pubmed

Enomoto K, Amano S, Sakurai K, Negishi N. [Two cases of postoperative local skin recurrence of breast cancer successfully treated with chemotherapy of irinotecan hydrochloride (CPT-11)]. Gan To Kagaku Ryoho. 2005;32:1782-5 pubmed

Inoue S, Hassan M, Kanetoshi A. [Topoisomerase I inhibitor (irinotecan hydrochloride)]. Nihon Rinsho. 2004;62 Suppl 12:456-60 pubmed

Terauchi F. [Irinotecan hydrochloride (CPT-11) for advanced cervical cancer]. Nihon Rinsho. 2004;62 Suppl 10:175-8 pubmed

Wilkinson K. Irinotecan hydrochloride. Clin J Oncol Nurs. 2001;5:179-80, 184 pubmed

Ma M, McLeod H. Lessons learned from the irinotecan metabolic pathway. Curr Med Chem. 2003;10:41-9 pubmed

Morimoto K, Kou M, Kinoshita H. [Irinotecan hydrochloride for treatment of advanced breast cancers]. Nihon Rinsho. 2000;58 Suppl:265-70 pubmed

Berg D. Irinotecan hydrochloride: drug profile and nursing implications of a topoisomerase I inhibitor in patients with advanced colorectal cancer. Oncol Nurs Forum. 1998;25:535-43 pubmed

Saijo N. Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecin injection) in Japan. Ann N Y Acad Sci. 1996;803:292-305 pubmed

Furue H. [Irinotecan hydrochloride (CPT-11)]. Gan To Kagaku Ryoho. 1994;21:709-17 pubmed